ADVANCED MEDICAL SOLUTIONS GROUP PLC (AMS) — Research Note

Executive summary

AMS is a UK-listed specialist in tissue-healing technologies (surgical adhesives, sutures, biosurgical collagens, and advanced woundcare dressings under brands like LiquiBand®, RESORBA®, LIQUIFIX™ and ActivHeal®), with FY25 revenue of £228.9m and ~£49.9m adjusted EBITDA. Over the five-year period the group transformed from a woundcare-heavy business into a diversified global surgical player via the 2024 Peters Surgical acquisition and delivered mid-single-digit organic growth plus one-off acquisition inflection. The single most important point for valuation today: the shares are subject to a recommended cash acquisition by H.B. Fuller at 285p/share, shareholder approval was obtained on 12 August 2026, and nearly all regulatory conditions are cleared — the stock is trading as merger arbitrage 2026-06-25 Recommended Cash Acquisition; 2026-09-16 Interim Results.

Fair value estimate

• Fair value range: 275p – 285p per share (implied market cap £600m – £620m).
• Methodology: deal-anchored / merger arbitrage. The Scheme of Arrangement price is 285p in cash; probability-weighting for a small residual break risk gives a mid-point ~282p, in line with the current price.
• Underlying fundamental value (pre-bid trading multiple of ~11-12x FY26 EBITDA of £55.1m gives EV ~£605-660m, i.e. ~200-230p/share) is well below the deal price. The undisturbed 3-month VWAP prior to the offer period was 205p and the 12-month high pre-bid was 229p — the deal represents a 39% premium to undisturbed VWAP 2026-06-25 Recommended Cash Acquisition.
• Deal EBITDA multiple: 12.9x pre-synergy 2026 EBITDA (management uses IFRS basis) 2026-06-25 Recommended Cash Acquisition.
• vs. current mcap of £613.7m: upside to the 285p bid is only ~1.1%. In a deal-break scenario the shares would likely revert toward 205-220p, i.e. downside of ~22-27%.

Sector context

• Sector: Health Care / Medical Devices — confirmed. AIM-listed UK specialist medtech.
• Quality/growth/leverage profile: above-average for the sector on gross margin (~54%) and return profile, but recent leverage has risen to 1.2x net debt/EBITDA following the Peters Surgical deal, still comfortably within covenant headroom (3.0x max) 2026-09-16 Interim Results.
• Listed peers: Convatec (LSE:CTEC), Smith & Nephew (LSE:SN.), Molnlycke (private), Integra LifeSciences (US). AMS is smaller and more focused than these but has been valued at a deal multiple similar to sector M&A benchmarks.

Investment thesis (3 bullets)

1. Near-certain cash return at 285p. Shareholder vote passed (12 Aug 2026), Austrian, German, UK CMA and Austrian FDI clearances all obtained; only a handful of residual conditions remain, with completion expected in Q4 2026 2026-09-16 Interim Results.
2. Fundamentally sound business as downside protection if deal broke. Diversified surgical portfolio, 22.7% adjusted EBITDA margin in H1 2026, £115.5m H1 revenue growing 4% reported, resilient end-market demand 2026-09-16 Interim Results.
3. Structural M&A appeal validated. Peters Surgical integration on track and Woundcare restructuring delivered margin improvement (from 8.1% to 9.4% adjusted operating margin H1 26 vs H1 25) — proves the underlying franchise is attractive to strategic buyers, providing a bid floor in a re-solicitation scenario 2026-09-16 Interim Results.

Key risks (3 bullets)

1. Deal break / delay risk. Remaining conditions 3(f)-(g) (France/Luxembourg FDI) and other approvals could delay or in a low-probability case scupper the deal; long-stop date is 25 June 2027 2026-06-25 Recommended Cash Acquisition.
2. No dividend and negligible upside optionality. Board suspended the interim dividend (Nil vs 0.85p prior year) pending completion; the ~1% spread to the offer is the maximum realistic upside 2026-09-16 Interim Results.
3. Restructuring execution and exceptionals still running through P&L. H1 26 reported PBT collapsed to £0.3m (vs £8.5m) due to £12.4m of exceptional items linked to site closures and deal costs; if the deal broke, fundamental reported earnings would look weak in the near term 2026-09-16 Interim Results.

Operating leverage

AMS is a mid-scale industrial-medtech business with moderate operating leverage. Cost base is roughly balanced between fixed manufacturing/regulatory/R&D overhead (~£12-15m R&D annually, ~9 manufacturing sites globally, ~1,800 employees) and variable COGS. Gross margin ran at 54.5% in H1 2026 (up 100bps YoY), with adjusted EBITDA margin at 22.7%. A 10% revenue beat over current expectations would likely translate to ~15-20% higher EBITDA — meaningful but not the transformative operating leverage of a software/platform business. The current operational synergy programme (closing five sutures/collagen sites in Germany and Czechia by March 2027) targets £10m annual savings, which if achieved would represent ~4% of revenue dropping mostly to EBITDA — evidence that scale benefits exist but require deliberate restructuring rather than being automatic on incremental volume 2026-09-16 Interim Results; 2025-09-17 Interim Results.

Value-trap signals

None identified relevant to current valuation — the stock is deal-locked at 285p. Prior to the bid, the shares had traded in a 177-239p range for 18 months despite strong revenue growth, which the Board attributed to market under-appreciation of the strategy 2026-06-25 Recommended Cash Acquisition.

Earnings vs. expectations

• H1 2026 (16 Sep 2026): Revenue £115.5m vs 20 July trading update guidance of £115.2m — in line. FY EBITDA still guided in line with consensus (£55.1m) 2026-09-16; 2026-07-20.
• FY 2025 (18 Mar 2026 prelim): Revenue £228.9m vs 15 Jan trading update guidance of ~£228.5m and adjusted EBITDA £49.5-50.0m — met 2026-01-15.
• H1 2025 (17 Sep 2025): Revenue £110.8m in line with 15 July trading update of ~£110m — met; PBT £16.4m adjusted 2025-09-17; 2025-07-15.
• FY 2024 (14 Jan 2025 trading update): Revenue ~£177m and EBITDA £40-40.5m — in line with consensus 2025-01-14.
• FY 2023 (H2 profit warning 4 Sep 2023): Revenue guidance cut to £124-127m and adjusted PBT to £25-27m from prior consensus due to Organogenesis royalty removal and US LiquiBand destocking — miss 2023-09-04.
• Pattern: One material downgrade in Sept 2023, otherwise reliable meet-in-line delivery for the last 8+ reporting periods. Since 2024, management has been consistent.

Conviction

Conviction: 4 (high).

• Anchors: (1) the fair-value call is anchored to a legally-binding recommended offer at 285p with shareholder approval already secured; (2) most regulatory conditions are cleared; (3) the market price is already very close to 285p, so the pricing view is close to consensus and self-evident.
• Caveats: (1) small residual regulatory/deal-break risk means the fair-value point estimate is not certain to be realised; (2) if the deal breaks, my underlying fundamental fair value (200-230p) is a wider-range judgment that would then become the relevant anchor.

Not conviction 5 because the deal has not yet completed.

Fit for this investor

Poor fit. This is not an AI-receiver — tissue adhesives and surgical sutures have no meaningful exposure to AI capex or agentic-AI-driven productivity. Operating leverage is moderate at best. Valuation offers only ~1% upside to the take-out price with ~25% downside if the deal breaks. It functions as a cash-equivalent with a small deal-arb spread, not a growth investment.